Home » Newsletters » BioWorld Science

BioWorld Science

July 15, 2019

View Archived Issues

Slt-deficient F. novicida mutant shows attenuation and protects against pneumonic challenge in mice

Allist Pharmaceuticals initiates phase III FLAG study of alflutinib mesylate in NSCLC

EIP Pharma initiates phase II study of neflamapimod in cognitive dysfunction associated with DLB

Recruitment ongoing in phase I study of BI-836880 for the treatment of wAMD

Results presented from phase III EAT2TREAT study of fampridine and acetazolamide

Roche presents interim results from part 1 of FIREFISH study of risdiplam

CD73 target defined for subgroup of AML precision medicine

How mothers drive their offspring to drink

FibroGen reports phase II data for pamrevlumab in patients with DMD

Large-scale mapping uncovers protein interactions

Betta Pharmaceuticals presents BRD4 inhibitors

New CRISPR/Cas9 transgenic mice with mutated F8 gene as a model for the study of hemophilia A

Mutations in F153S of integrin beta 3 affect integrin and platelet functions

Chiesi Farmaceutici divulges new ROCK1 and ROCK2 inhibitors

Bodyweight-adjusted rivaroxaban treatment in children with acute venous thromboembolism

Chinese researchers divulge IDO1 inhibitors

Galderma describes new mTOR inhibitors

Angex Pharmaceutical discloses protein kinase inhibitors

Remegen's phase II study of RC-18 meets primary endpoint in SLE

Phase III study of niraparib maintenance therapy in first-line ovarian cancer meets primary endpoint

Pivotal Japanese studies of JTZ-951 in CKD anemia meet primary endpoints

FDA issues complete response letter for Farxiga in type 1 diabetes

Prescient initiates phase Ib trial of PTX-100 in advanced malignancies

Capricor presents 6-month data analysis from HOPE-2 trial of CAP-1002 in DMD

Neon Therapeutics reports phase Ib topline data on NEO-PV-01

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...